Page 2 - Lupin Ltd News

Why pharma stocks are emerging as safe bet amid global market turmoil

The pharma sector is seen as a safe bet because demand remains steady even during inflation or economic slowdowns. Besides, companies earn revenue from multiple global markets, which helps reduce risk

Stocks to watch today: Adani stocks, JSW Steel, Indian Oil, Astral, Lupin

Stocks to Watch today, May 19, 2026: Adani Group stocks, Indian Oil, JSW Steel, Astral, and Lupin are some of the key stocks to watch today

Stocks to Watch today: BSE, MRF, L&T, Paytm, Meesho, Biocon, Bajaj Auto

Stocks to Watch today, May 7, 2026: Mahindra Lifespaces, Deepak Fertilizers, Newgen Software, and Pidilite Industries are among the top stocks to watch today

Nifty Midcap Select index hits record high, rallies 13% in one month

The Nifty Midcap Select index hit a new high of 14,223.90, soaring 2% and surpassing its previous high of 14,118 touched on December 1, 2025.

Nifty Pharma hits 52-wk high; Wockhardt up 15%, Laurus, Lupin at new peaks

The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.

Nifty Apr F&O rollovers hint at cautious stance; ONGC among stocks in focus

The Nifty rollovers to May were below average, suggesting a likely cautious stance among participants and slight hesitation to carry forward aggressive bets, says Axis Securities.

Nifty Pharma index soars 3%; Dr Reddy's, Piramal Pharma rally up to 9%

Glenmark Pharma, Cipla, Wockhardt, Mankind Pharma, Lupin, Zydus Life, Laurus, Ipca Labs, Divis Labs, Strides Pharma and Onesource were up in the range of 3% to 6%.

Lupin's US arm signs $30 million litigation settlement with Humana Inc

Pharma major Lupin Ltd on Friday said its arm Lupin Pharmaceuticals, Inc USA has entered into a USD 30 million settlement agreement with Humana Inc for litigation over alleged anti-competitive practices. Lupin Pharmaceuticals, Inc USA (LPI) has been involved in multiple civil lawsuits alleging anti-competitive behaviour related to certain products and violation of federal and state antitrust laws. These multiple civil lawsuits were then combined into the collection of similar cases referred to as 'In Re Generic Pharmaceuticals Antitrust Litigation' located in Philadelphia, Pennsylvania, Lupin said in a regulatory filing. "While LPI denies the allegations, bu considering that other defendants have recently settled the case and in order to avoid the costs and uncertainties of continued litigation, LPI has entered into a settlement agreement with one of the plaintiffs namely Humana Inc. (Humana)," it added. Under the terms of the agreement, LPI will pay USD 30 million in consideration

Lupin arm settles US antitrust litigation with Humana for $30 million

Lupin says its US subsidiary will pay $30 million to Humana to settle antitrust claims, adding the amount has already been provided for and does not impact current financials